Noor Gajraj, MD
Pain Medicine · Plano, TXNPI 1205922390
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $66,579 of the $85,240 with a category attached, or 78.1%. 49 manufacturers reported payments, led by Daiichi Sankyo Inc. at 29.8% of the total. Reporting peaked in 2019 at $46,589 and has fallen 99.4% since, to $285 in 2025. Among pain medicine clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 518 payments — averaging $164.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Daiichi Sankyo Inc.$25K
- MDD US Operations, LLC$25K
- Scilex Pharmaceuticals Inc.$15K
- Amgen$5K
- Redhill Biopharma Inc.$4K
- Indivior Inc.$3K
- plus $8K from 43 others
What the payments were for
- Consulting fees$1,2001%
- Speaking & faculty fees$66,57978%
- Travel & lodging$7,9189%
- Food & beverage$9,52311%
- Education$50%
- Gifts$140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Morphabond ER$24,486
- Lucemyra/Lofexidine$23,488
- ZTLido$15,180
- RAYOS$5,640
- MOVANTIK$3,640
- SUBLOCADE$2,987
- DUEXIS$1,680
- NURTEC ODT$1,200
- KRYSTEXXA$800
- Prolate$675
- QULIPTA$249
- Nalocet$225
- Nucynta ER$180
- SACROILIAC JOINT FUSION SYSTEM$163
- CellerateRx$141
- GENERAL - THERAPIES$129
- BRIXADI$126
- UBRELVY$124
- Dayvigo$119
- RELISTOR$104
How this compares
$85,240 in reported general payments places this provider in the 95th percentile of 583 pain medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RelistorMethylnaltrexone Bromide | 18 | $42,287 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 1,256 | $34,003 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 49 | $31,157 |
| OxycontinOxycodone Hcl | 46 | $27,434 |
| Xtampza ErOxycodone Myristate | 39 | $27,168 |
| Nucynta ErTapentadol Hcl | 23 | $22,214 |
| BelbucaBuprenorphine Hcl | 20 | $15,805 |
| Buprenorphine | 42 | $15,745 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 478 | $15,368 |
| Buprenorphine Hcl | 341 | $12,061 |
| MovantikNaloxegol Oxalate | 24 | $10,435 |
| LinzessLinaclotide | 14 | $7,778 |
| Fentanyl | 71 | $7,666 |
| DayvigoLemborexant | 12 | $7,608 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 59 | $6,356 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Xtampza Er, Nucynta Er, Belbuca | $1,312 | $65,18782 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor | $595 | $42,28718 claims |
| Indivior Inc.Suboxone | $3,195 | $31,15749 claims |
| Redhill Biopharma Inc.Movantik | $3,754 | $10,43524 claims |
| AbbVieLinzess | $528 | $7,77814 claims |
| Eisai Inc.Dayvigo | $191 | $7,60812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 583 pain medicine providers in Texas.
Other pain medicine in Plano
- Jonathan KoningPlano$47K
- Melissa MurphyGrapevine$653K
- Shiraz YazdaniLubbock$514K
- Aaron CalodneyTyler$296K
- Candice BurnetteSugar Land$265K
- Ashley Bailey-ClassenFort Worth$244K
- Grant ChenHouston$175K
- Gunjan PatelHouston$166K
- Anthony BergRockwall$165K
- Puneet SayalCorpus Christi$153K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.